You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis

    SBC: Stemsynergy Therapeutic            Topic: 102

    DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Simultaneous kinetic analyses of neuronal connectivities

    SBC: CIENCIA INC            Topic: 101

    DESCRIPTION provided by applicant Aberrant neuronal connectivity is associated with a number of neuropathological and neuropsychiatric diseases disorders Inefficient developmental connectivity misdirected connectivity or disrupted and degenerated connectivity can account for losses of normal neuronal communication and subsequent losses of mental or physical health Altered expression of axon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications

    SBC: ASSUAGE PHARMACEUTICALS, INC.            Topic: NIAAA

    PROJECT SUMMARY Alcohol addiction and disorders associated to excessive alcohol use are a serious public health problem in the United States and in other parts of the world Current pharmacotherapies for the treatment of these disorders show limited efficacy Preclinical and clinical findings point to nicotinic acetylcholine receptors nAChRs as an alternative promising target for the developmen ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseases

    SBC: Azitra Inc.            Topic: NIAID

    PROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Stabilization of Influenza Vaccine by Silica-Coating

    SBC: STONESTABLE, INC.            Topic: NIAID

    The goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under ambient environmental conditions Currently vaccines are either stabil ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings

    SBC: Discidium Biosciences, LLC            Topic: NIAID

    Antiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Product Development of Intensity Modulation for Bolus Electron Conformal Therapy

    SBC: Decimal, LLC            Topic: 102

    Project Summary Abstract Electron beam therapy EBT using MeV beams provides effective radiation treatment for superficial cancers depthandlt cm As many as of radiotherapy patients in USA annually are eligible for electron therapy for some portion of their treatment making it the second most used external beam modality As many as of these electron patients ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government